SCHEMBL31199293

SCHEMBL31199293

Cc1cc(O)c(-c2ccc(N3CCO[C@H](CO)C3)nn2)c(F)c1

nearest known ligand 0.37

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 1/20 0.37
IL1B P01584 2/20 0.37
NLRP3 Q96P20 2/20 0.37
PIK3CD O00329 2/20 0.36
PIK3CA P42336 2/20 0.36
PIK3CB P42338 2/20 0.36
PIK3CG P48736 2/20 0.36
PIK3C2B O00750 1/20 0.36
MTOR P42345 1/20 0.36
LRRK2 Q5S007 4/20 0.36
ADORA2A P29274 1/20 0.36
ADORA1 P30542 1/20 0.36
SCD O00767 6/20 0.35
CNR2 P34972 2/20 0.35
RAF1 P04049 1/20 0.34
BRAF P15056 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31199817 0.91 IL1B (0.45) AKT1IL1BNLRP3PIK3CDPIK3CA
SCHEMBL31199314 0.91 IL1B (0.45) AKT1IL1BNLRP3PIK3CDPIK3CA
SCHEMBL31199666 0.89 LRRK2 (0.37) AKT1IL1BNLRP3PIK3CDPIK3CA
SCHEMBL31199386 0.88 PIK3CD (0.41) AKT1IL1BNLRP3PIK3CDPIK3CA
SCHEMBL31199399 0.87 PIK3CD (0.43) IL1BNLRP3PIK3CDPIK3CAPIK3CB
SCHEMBL31199673 0.87 PIK3CD (0.39) AKT1IL1BNLRP3PIK3CDPIK3CA
SCHEMBL31199628 0.85 AKT1 (0.42) AKT1PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL31199471 0.84 CNR2 (0.44) AKT1PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL31199374 0.84 IL1B (0.44) AKT1IL1BNLRP3CNR2
SCHEMBL31199411 0.84 IL1B (0.44) AKT1IL1BNLRP3CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4680601-A1 PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES Sanofi (FR) 2026-01-21 EP claimed
US-20240360151-A1 PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES SANOFI (FR) 2024-10-31 US claimed
WO-2024188994-A1 PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES SANOFI (FR) 2024-09-19 WO claimed
EP-4680601-A1 PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES Sanofi (FR) 2026-01-21 EP disclosed
US-20240360151-A1 PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES SANOFI (FR) 2024-10-31 US disclosed
WO-2024188994-A1 PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES SANOFI (FR) 2024-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360151-A1 PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES NLRP3, NOD1, NLRP1 AKT1 1588/4885IL1B 66/4885NLRP3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.